Loading clinical trials...
Loading clinical trials...
Long-term Safety of Umbilical Cord-Mesenchymal Stem Cell (UC-MSC) Transplantation in Patients With Retinitis Pigmentosa
The study will perform to follow-up UC-MSCs and CM transplantation. 18 patients will be called back to be examined after 5 years of UC-MSC and/or CM transplantation.
The study will be performed on 18 patients who received UC-MSC and CM transplantation in 2018. The study is included as retrospective cohort since the transplantation happened 5 years ago. Patients will do a visual field test, visual acuity test, electroretinography, funduscopy, and Optical Coherence Tomography examination. The observation results will be written in the observation table and analyzed by a statistic.The study will be performed at Rumah Sakit Jakarta Eye Center and Rumah Sakit Umum Pusat Dr. Sardjito Yogyakarta.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Jakarta Eye Center Hospital
Jakarta, DKI Jakarta, Indonesia
Sardjito Hospital
Yogyakarta, Special Region, Indonesia
Start Date
May 1, 2026
Primary Completion Date
July 1, 2027
Completion Date
September 1, 2027
Last Updated
February 25, 2026
18
ESTIMATED participants
Conditioned Medium (CM)
BIOLOGICAL
Umbilical Cord Mesenchymal Stem Cell (UC-MSC)
BIOLOGICAL
Lead Sponsor
PT. Prodia Stem Cell Indonesia
NCT05926583
NCT07174726
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07292987